Welcome!

News Feed Item

Bone Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

Bone Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Bone Cancer Global Clinical Trials Review, H1, 2014" provides data on the Bone Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bone Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bone Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Bone Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Bone Cancer 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Bone Cancer Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Bone Cancer 37
Jan 03, 2014: Eleison Announces Achievement of Enrollment Milestone in its Phase II Trial of ILC for Pediatric Bone Cancer 37
Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 37
Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer 37
Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235 38
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 38
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
Novartis AG 40
Clinical Trial Overview of Novartis AG 40
F. Hoffmann-La Roche Ltd. 46
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 46
Amgen Inc. 48
Clinical Trial Overview of Amgen Inc. 48
Bayer AG 50
Clinical Trial Overview of Bayer AG 50
Takeda Pharmaceutical Company Limited 52
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 52
Merck & Co., Inc. 53
Clinical Trial Overview of Merck & Co., Inc. 53
Pfizer Inc. 54
Clinical Trial Overview of Pfizer Inc. 54
AstraZeneca PLC 55
Clinical Trial Overview of AstraZeneca PLC 55
Eli Lilly and Company 56
Clinical Trial Overview of Eli Lilly and Company 56
Algeta ASA 57
Clinical Trial Overview of Algeta ASA 57
Clinical Trial Overview of Top Institutes / Government 58
National Cancer Institute 58
Clinical Trial Overview of National Cancer Institute 58
Children's Oncology Group 67
Clinical Trial Overview of Children's Oncology Group 67
The University of Texas M. D. Anderson Cancer Center 70
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 70
Memorial Sloan Kettering Cancer Center 72
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 72
Massachusetts General Hospital 74
Clinical Trial Overview of Massachusetts General Hospital 74
European Organization for Research and Treatment of Cancer 75
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 75
Southwest Oncology Group 76
Clinical Trial Overview of Southwest Oncology Group 76
University Health Network 77
Clinical Trial Overview of University Health Network 77
Stanford University 78
Clinical Trial Overview of Stanford University 78
Five Key Clinical Profiles 79
Appendix 180
Abbreviations 180
Definitions 180
Research Methodology 181
Secondary Research 181
About GlobalData 182
Contact Us 182
Disclaimer 182
Source 183

List of Tables

Bone Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Bone Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Bone Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 40
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 46
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 48
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 50
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 52
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 53
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 54
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 55
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 56
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Algeta ASA, 2014* 57
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 58
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 67
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 70
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 72
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 74
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 75
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 76
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 77
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 78

List of Figures

Bone Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 181

Read the full report:
Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone in...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices t...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to clos...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that's no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, explored how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He expla...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...